Graft-versus-host disease future or investigational therapies

Revision as of 22:30, 15 June 2017 by Shyam Patel (talk | contribs)
Jump to navigation Jump to search

Graft-versus-host disease

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Graft-versus-host disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Graft-versus-host disease future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Graft-versus-host disease future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Graft-versus-host disease future or investigational therapies

CDC on Graft-versus-host disease future or investigational therapies

Graft-versus-host disease future or investigational therapies in the news

Blogs on Graft-versus-host disease future or investigational therapies

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Graft-versus-host disease future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] {shyam}}

Overview

Future or Investigational Therapies

  • Regarding diagnostics, early and more sensitive diagnostic strategies are being studied. Wireless capsule endoscopy has been proposed for upper GI GvHD diagnosis.[1] A pilot study of 15 patients showed that wireless capsule endoscopy could be a novel method for early GI GvHD diagnosis. The benefits are that this procedure is less invasive that a traditional endoscopy and bypasses the potential problem of false negatives, given patchy distribution of inflammation in GI GvHD.[1]
  • Regarding therapeutics, there are a few medications that are currently being investigated for GvHD treatment. Such examples include ibrutinib (a Bruton's tyrosine kinase inhibitor) and ruxolitinib (a JAK2 inhibitor). These medications are not formally FDA-approved thus far, but they may become approved in the near future pending further clinical studies.

There are a large number of clinical trials either ongoing or recently completed in the investigation of graft-versus-host disease treatment and prevention[2].

References

  1. 1.0 1.1 Coron E, Laurent V, Malard F, Le Rhun M, Chevallier P, Guillaume T; et al. (2014). "Early detection of acute graft-versus-host disease by wireless capsule endoscopy and probe-based confocal laser endomicroscopy: results of a pilot study". United European Gastroenterol J. 2 (3): 206–15. doi:10.1177/2050640614529283. PMC 4212456. PMID 25360304.
  2. http://www.clinicaltrial.gov/ct2/results?term=Graft-versus-host+disease search of clinicaltrials.gov for Graft-versus-host disease]